x
Breaking News
0

Alexion Pharmaceuticals Inc (ALXN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Alexion's earnings

Delivery Method

Status

Add to/Remove from a Portfolio My Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
130.74 -1.05    -0.80%
24/07 - Closed. Currency in USD ( Disclaimer )
After Hours
131.00
+0.26
+0.20%
24/07
Type: Equity
Market: United States
ISIN: US0153511094 
CUSIP: 015351109
  • Volume: 1,749,521
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 130.19 - 132.22
START TRADING NOW
Alexion 130.74 -1.05 -0.80%

ALXN Overview

 
Information about the Alexion Pharmaceuticals Inc Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close131.79
Day's Range130.19 - 132.22
Revenue3.95B
Open132.03
52 wk Range96.18 - 145.41
EPS2.11
Volume1,749,521
Market Cap29.59B
Dividend (Yield)0 (N/A)
Average Vol. (3m)3,144,667
P/E Ratio62.58
Beta1.43
1-Year Change3.93%
Shares Outstanding224,556,542
Next Earnings DateJul 27, 2017

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Sell Buy Buy Buy
Technical Indicators Strong Sell Strong Sell Neutral Strong Buy Sell
Summary Strong Sell Strong Sell Neutral Strong Buy Neutral

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Harami Bearish 30 Current
Completed Patterns
Engulfing Bearish 5H 1 Jul 24, 2017 07:00AM
Three Inside Up 1W 2 Jul 09, 2017
Three Outside Down 30 5 Jul 24, 2017 01:00PM

Alexion Pharmaceuticals Inc News & Analysis

Alexion Pharmaceuticals Inc Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 130.74 0.00 0.00 1,749,521 -0.80% USD 24/07  
  Munich 111.95 0.00 0.00 0 +1.07% EUR 24/07  
  Stuttgart 111.95 0.00 0.00 20 -0.27% EUR 24/07  
  TradeGate 112.05 112.12 112.49 153 -0.30% EUR 24/07  
  Frankfurt 112.77 112.01 112.48 33 +0.75% EUR 24/07  
  Xetra 112.20 111.60 113.20 394 +0.40% EUR 24/07  
  Berlin 112.04 112.08 112.33 0 +1.07% EUR 24/07  
  Vienna 111.750 0.000 0.000 0 0.00% EUR 21/07  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Alphabet Inc C 980.34 986.20 970.77 +7.42 +0.76% 3.25M 24/07  
  Alphabet A 998.31 1,006.19 990.27 +4.47 +0.45% 3.98M 24/07  
  Apple 152.09 152.44 149.90 +1.82 +1.21% 21.49M 24/07  
  Boeing 212.18 212.64 211.40 +0.04 +0.02% 2.39M 24/07  
  Bank of America 23.91 24.03 23.73 +0.11 +0.46% 51.38M 24/07  
  Bharti Infratel 421.45 425.00 414.90 +12.55 +3.07% 1.12M 04:43:00  
  Tesla 342.52 343.40 330.01 +14.12 +4.30% 8.64M 24/07  
  AXIS Bank 532.45 537.40 529.95 -2.35 -0.44% 1.42M 04:43:00  
  Reliance Industries 1,613.75 1,624.95 1,610.00 -1.50 -0.09% 1.45M 04:43:00  
  Tata Steel Ltd 551.85 554.00 548.75 +3.35 +0.61% 783.51K 04:43:00  

Alexion Pharmaceuticals Inc Company Profile

IndustryMajor Drugs
SectorHealthcare
Employees

3121

Equity Type

ORD

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading

My Sentiments

Add your sentiment:
or
 
Members' Sentiments:
Bullish
50%
Bearish
50%

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Latest ALXN Comments

Charles Patterson
Charles Patterson May 24, 2017 5:09PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What do they do?
Reply
0 0
Joel Hanson
Joel Hanson Dec 12, 2016 3:27PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
TP of $171.75 by 22 analyst, 18 buy, 4 hold. ALXN had typical mass hysteria to CEO/CFO resigning. Get in now that these loons have dropped all their shares.
Reply
0 0
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Please wait a minute before you try to comment again.
 
 
 
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Add Chart to Comment
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email